Androgen Deprivation Therapy News and Research

RSS

Endostatin can decrease proliferation of castration-resistant prostate cancer cells

Failure of hormone deprivation therapy, which is used to slow prostate cancer in patients, leads to castration-resistant prostate cancer, a lethal form of advanced disease with limited treatment options.

10 Mar 2017

Combination therapy that targets immune-busting cells effective in treating advanced prostate cancer

Advanced prostate cancer resistant to castration therapy appears to respond well to a combination of immune checkpoint blockades and treatments that target certain immune-busting cells commonly associated with poor patient prognosis and therapy resistance.

10 Mar 2017

ADT for treating advanced prostate cancer not linked to increased risk of Alzheimer disease

A large-scale, population based study led by Dr. Laurent Azoulay, Senior Investigator with the Lady Davis Institute at the Jewish General Hospital, has concluded that the use of androgen deprivation therapy (ADT) to treat advanced prostate cancer is not associated with an increased risk of Alzheimer disease.

27 Jan 2017

Roswell Park researchers identify gene signatures that may help predict fatal prostate cancers

Standard therapy for prostate cancer, the third-leading cause of cancer-related deaths in American men, is based on blocking androgens, the male sex hormones.

11 Jan 2017

Common hormone therapy to treat prostate cancer may increase dementia risk in men

A common hormone therapy to treat prostate cancer may double a man's risk of dementia, regardless of his age, Penn Medicine researchers reported in a study published online today in JAMA Oncology.

14 Oct 2016

African-American men treated with ADT for prostate cancer suffer from high mortality rates

In a retrospective study analyzing patients' medical records, researchers at Brigham and Women's Hospital found that patients' race significantly affected their longevity by increasing the likelihood of death after receiving androgen deprivation therapy (ADT).

5 Aug 2016

Study finds evidence that PD-1 antibody may benefit men with metastatic prostate cancer

Restoring tumor-specific immunity is a treatment strategy that works well in melanoma and lung cancer patients. Now a new study out of the OHSU Knight Cancer Institute is reviving hope that the approach also may help men with life-threatening prostate cancer.

14 Jul 2016

Romosozumab for postmenopausal women with osteoporosis meets co-primary endpoints in Phase 3 study

Amgen and UCB today announced top-line results from the Phase 3 placebo-controlled FRActure study in postmenopausal woMen with ostEoporosis (FRAME).

22 Feb 2016

Vanderbilt physicians examine risk factors for cardiovascular disease in prostate cancer survivors

The 3 million prostate cancer survivors in the United States are likely to die from something other than cancer, thanks to early detection, effective treatment and the disease's slow progression.

11 Feb 2016

Docetaxel remains effective in prostate cancer even after treatment with androgen-deprivation therapy

A study presented at the 2016 Genitourinary Cancers Symposium shows that 40 percent of patients with castration-resistant metastatic prostate cancer (mCRPC) treated with docetaxel following abiraterone had at least 50 percent reduction in prostate specific antigen (PSA), demonstrating the activity of this drug sequencing.

11 Jan 2016

New discovery may soon make prostate cancer cells easier to destroy

A newly discovered connection between two common prostate cancer treatments may soon make prostate cancer cells easier to destroy. Drugs that could capitalize on the discovery are already in the pipeline, and a clinical trial to test whether the finding could improve treatments for prostate cancer patients could be only a few years away.

20 Dec 2015

Androgen deprivation therapy elevates Alzheimer’s risk

US researchers find that androgen deprivation therapy increases the risk of Alzheimer’s disease in men with prostate cancer, with the risk rising with greater duration of therapy.

11 Dec 2015

Androgen deprivation therapy for prostate cancer may up Alzheimer's disease risk

Men taking androgen deprivation therapy (ADT) for prostate cancer were almost twice as likely to be diagnosed with Alzheimer's disease in the years that followed than those who didn't undergo the therapy, an analysis of medical records from two large hospital systems by Penn Medicine and Stanford University researchers has shown.

8 Dec 2015

MicroRNA reduces tumor growth, increases cell death in castration-resistant prostate cancer

Researchers at the UC Davis Comprehensive Cancer Center have shown that the microRNA, miR-124, reduced tumor growth and increased cell death in castration-resistant prostate cancer.

17 Nov 2015

Prostate cancer patients more likely to receive medical care matched to level of risk

After decades of overtreatment for low-risk prostate cancer and inadequate management of its more aggressive forms, patients are now more likely to receive medical care matched to level of risk, according to a study by researchers at UC San Francisco.

25 Jul 2015

Prostate cancer patients can experience cognitive impairment following androgen deprivation therapy

Cognitive impairment can occur in cancer patients who are treated with a variety of therapies, including radiation therapy, hormone therapy, and chemotherapy.

14 May 2015

Prostate cancer patients who receive androgen deprivation therapy may experience cognitive problems

Cognitive impairment can occur in cancer patients who are treated with a variety of therapies, including radiation therapy, hormone therapy, and chemotherapy. After chemotherapy treatment it is commonly called "chemo brain." Signs of cognitive impairment include forgetfulness, inability to concentrate, problems recalling information, trouble multi-tasking and becoming slower at processing information.

13 May 2015

Moffitt scientists examine why prostate cancer patients who receive ADT experience hot flashes

Androgen deprivation therapy (ADT) is a common treatment option for patients with advanced stage prostate cancer. But nearly 80 percent of patients who receive ADT report experiencing hot flashes during and after treatment. Moffitt Cancer Center researchers are working to determine what genetic factors and other characteristics might make prostate cancer patients more likely to experience hot flashes during and after therapy.

10 May 2015

Cholesterol-lowering statin drugs could delay prostate cancer growth in patients receiving ADT

Men who went on cholesterol-lowering statin drugs when they began androgen deprivation therapy for prostate cancer had a longer time in which their disease was under control than did men who didn't take statins, a clinical trial led by Dana-Farber Cancer Institute investigators shows.

8 May 2015

Men who receive brachytherapy more likely to be cancer-free five years later

Results from a randomised controlled trial to compare the use of permanent radioactive implants (brachytherapy) with dose-escalated external beam radiotherapy in patients with prostate cancer show that the men who received brachytherapy were twice as likely to be cancer-free five years later.

27 Apr 2015